Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1992-01-14
1994-03-01
Wityshyn, Michael G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 27, 514822, 530380, 530381, 530382, 530350, 530395, 530402, 530427, A61K 3700, A61K 3514
Patent
active
052907643
ABSTRACT:
Processes for stabilizing active PAI-1 protein comprising combining active PAI-1 protein with an aqueous buffer having an ionic strength of at least about 5 millisiemens and a sugar selected from the group consisting of monosaccharides and disaccharides, and/or subjecting the active PAI-1 protein to lyophilization, are disclosed. Also described are compositions, including pharmaceutical compositions and kits, which include the stabilized active PAI-1 protein, and therapeutic processes employing the same in the treatment of fibrinolysis.
REFERENCES:
patent: 4806524 (1989-02-01), Kawaguchi et al.
patent: 5112955 (1992-05-01), Wun
Arakawa et al, Biochemistry, vol. 21, No. 25, pp. 6536-6544, 1982.
Reilly et al, Chemical Abstracts, vol. 115, p. 589, Ref. #253188d., 1991.
Chandler et al., Clin. Chem. vol. 35, No. 5, pp. 787-793, 1989.
Rauby et al, Thrombosis and Haemostasis, vol. 62, No. 3, 917-922, 1989.
Ehrilich et al, Biochemistry, vol. 30, No. 4, pp. 1021-1028, 1991.
Medvescek et al, Chemical Abstracts, vol. 114, p. 527, Ref. #5255u., 1991.
Stump et al., Semin. Thromb. Hemos., vol. 16, No. 3, pp. 260-273 (1990).
Lijnen et al., Fibrinolysis, vol. 3, pp. 67-77 (1989).
Van Mourik et al., J. Biol. Chem., vol. 259, pp. 14914-14921 (1984).
Colucci et al., J. Clin. Invest., vol. 75, pp. 818-824 (1985).
Almer et al., Thromb. Research, vol. 47, pp. 335-339 (1987).
Hamsten et al., New England J. of Medicine, vol. 313, pp. 1557-1563 (1985).
Wiman et al., J. Lab. Clin. Med., vol. 105, pp. 265-270 (1985).
Colucci et al., J. Clin. Invest., vol. 78, pp. 138-144 (1986).
Ehrlich et al., J. Biol. Chem., vol. 265, pp. 13029-13035 (1990).
Reilly et al., J. Biol. Chem., vol. 265, No. 16, pp. 9570-9574 (1990).
Racanelli et al., Fibr., vol. 4, Suppl. 3, p. 43 (1990).
Vaughan et al. J. Clin. Invest., vol. 84, pp. 586-591 (1989)
Cramer et al., Blood, vol. 77, No. 4, pp. 694-699 (1991).
Timasheff et al., "Stabilization of Protein Structure By Solvents", in Protein Structure: A Practical Approach, T. E. Creighton, ed., IRL Press (1989).
Volkin et al., "Minimizing Protein Inactivation", in Protein Function: A Practical Approach, T. E. Creighton, ed., IRL Press (1989).
Keijer et al., Fibrinolysis, vol. 4, pp. 153-159 (1990).
Coleman et al., J. Biol. Chem., vol. 257, pp. 4260-4264 (1982).
Kruithof et al., Thromb. Haemostasis, vol. 59, pp. 7-12 (1988).
Booth et al., Eur. J. Biochem., vol. 165, pp. 595-600 (1987).
Andreasen et al., J. Biol. Chem., vol. 261, pp. 7644-7651 (1986).
Zeheb et al., Thromb. Haemostasis, vol. 58, pp. 1017-1023 (1987).
Hekman et al., J. Biol. Chem., vol. 260, pp. 11581-11587 (1985).
Lambers et al., J. Biol. Chem., vol. 262, pp. 17492-17496 (1987).
Ginsburg et al., J. Clin. Invest., vol. 78, pp. 1673-1680 (1986).
Ny et al., Proc. Natl. Acad. Sci. U.S.A., vol. 83, pp. 6776-6781 (1986).
Pannekoek et al., EMBO J. vol. 5, pp. 2539-2544 (1986).
Wun et al., FEBS Lett., vol. 210, pp. 11-16 (1987).
Alessi et al., Eur. J. Biochem., vol. 175, pp. 531-540 (1988).
Andreasen et al., FEBS Lett., vol. 209, pp. 213-218 (1986).
Sisk et al., Gene (Amst.), vol. 96, pp. 305-309 (1990).
Remington's, Pharmaceutical Sciences, Gennaro, A. R., ed., Mack Publishing Co., Easton, Pa. (1990) pp. 1435-1712.
The United States Pharmacopeia-The National Formulary, 22nd Revision, Mack Printing Company, Easton, Pa. (1990) pp. 1857-1859.
Coleman, J. Biol. Chem., vol. 261, pp. 4352-4357 (1986).
Lambers et al.,Fibrinolysis, vol. 2, Supp. 1, p. 33 (1988).
Kooistra et al., Biochem. J., vol. 239, pp. 497-503 (1989).
Franke et al., Biochem. Biophys. Acta., vol. 1037, pp. 16-23 (1990).
Duke, Jr. Jodie L.
Reilly Thomas M.
Walton, Jr. Harry L.
Mohamed Abdel A.
The DuPont Merck Pharmaceutical Company
Wityshyn Michael G.
LandOfFree
Stabilization of active plasminogen activator inhibitor-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stabilization of active plasminogen activator inhibitor-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stabilization of active plasminogen activator inhibitor-1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-577144